Kevzara(sarilumab)
Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Kevzara
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kevzara | Biologic Licensing Application | 2024-08-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 9 | 4 | 10 | 1 | 1 | 24 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 9 | 2 | 10 | 1 | 1 | 22 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 1 | — | — | 2 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | — | 2 | — | — | 2 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | — | — | 2 | — | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | 1 | — | — | 1 |
| Arteritis | D001167 | EFO_0009011 | I77.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 2 | — | — | — | 2 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 2 | — | — | — | 2 |
| Spondylarthritis | D025241 | — | — | — | 2 | — | — | — | 2 |
| Spondylitis | D013166 | — | M46.9 | — | 2 | — | — | — | 2 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | — | — | — | 1 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sarilumab |
| INN | sarilumab |
| Description | Sarilumab (human mab) |
| Classification | Antibody |
| Drug class | antiviral (arildone derivatives); monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108730 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NU90V55F8I (ChemIDplus, GSRS) |
Target
Agency Approved
IL6R
IL6R
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Kevzara – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,558 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kevzara
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,040 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use